logo
Plus   Neg
Share
Email

Baudax Bio's (BXRX) Non-opioid Pain Drug Makes It To The Finish Line

Baudax Bio Inc. (BXRX) has received FDA approval for ANJESO, which is indicated for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.

ANJESO that will be administered as a once-a-day intravenous (IV) bolus push is the only available 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) and offers once-daily dosing.

Baudax expects ANJESO to be available in the U.S. in late April or early May 2020.

Esther Hong, an analyst at Janney Montgomery, estimates peak sales of the drug in the U.S. to reach about $355 million.

Baudax Bio is a spinoff from Recro Pharma Inc (REPH), and it began trading on the NASDAQ Capital Market on November 22, 2019.

The first time we alerted readers to BXRX was on November 27, 2019, when it was trading around $6. The second time we reminded readers about the impending catalyst was on February 13, 2020, when the stock was trading around $8.

BXRX has thus far hit a low of $3.57 and a high of $9.60. The stock closed Thursday's trading at $7.90, up 0.77%. In after-hours, it was up 29.11% at $10.20.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT